DeWald L, Starr C, Butters T, Treston A, Warfield K
Antiviral Res. 2020; 184:104881.
PMID: 32768411
PMC: 7405907.
DOI: 10.1016/j.antiviral.2020.104881.
Chen C, Huang J, Wang C, Tahara S, Zhou L, Kondo Y
Nat Commun. 2017; 8:13882.
PMID: 28067225
PMC: 5227552.
DOI: 10.1038/ncomms13882.
Teimourpour R, Tajani A, Askari V, Rostami S, Meshkat Z
Iran J Pathol. 2016; 11(3):222-230.
PMID: 27799971
PMC: 5079455.
Khachatoorian R, French S
World J Hepatol. 2016; 8(1):9-35.
PMID: 26783419
PMC: 4705456.
DOI: 10.4254/wjh.v8.i1.9.
Hundt J, Li Z, Liu Q
World J Gastroenterol. 2014; 19(47):8929-39.
PMID: 24379618
PMC: 3870546.
DOI: 10.3748/wjg.v19.i47.8929.
Tupaia CD81, SR-BI, claudin-1, and occludin support hepatitis C virus infection.
Tong Y, Zhu Y, Xia X, Liu Y, Feng Y, Hua X
J Virol. 2010; 85(6):2793-802.
PMID: 21177818
PMC: 3067968.
DOI: 10.1128/JVI.01818-10.
Mutagenesis of the fusion peptide-like domain of hepatitis C virus E1 glycoprotein: involvement in cell fusion and virus entry.
Li H, Huang C, Ai L, Chuang C, Chen S
J Biomed Sci. 2009; 16:89.
PMID: 19778418
PMC: 2759930.
DOI: 10.1186/1423-0127-16-89.
Blocking hepatitis C virus infection with recombinant form of envelope protein 2 ectodomain.
Whidby J, Mateu G, Scarborough H, Demeler B, Grakoui A, Marcotrigiano J
J Virol. 2009; 83(21):11078-89.
PMID: 19710151
PMC: 2772786.
DOI: 10.1128/JVI.00800-09.
Genetic variability of hepatitis C virus before and after combined therapy of interferon plus ribavirin.
Cuevas J, Torres-Puente M, Jimenez-Hernandez N, Bracho M, Garcia-Robles I, Wrobel B
PLoS One. 2008; 3(8):e3058.
PMID: 18725975
PMC: 2518109.
DOI: 10.1371/journal.pone.0003058.
Dissecting the role of putative CD81 binding regions of E2 in mediating HCV entry: putative CD81 binding region 1 is not involved in CD81 binding.
Rothwangl K, Manicassamy B, Uprichard S, Rong L
Virol J. 2008; 5:46.
PMID: 18355410
PMC: 2277408.
DOI: 10.1186/1743-422X-5-46.
Replication-competent recombinant vesicular stomatitis virus encoding hepatitis C virus envelope proteins.
Tani H, Komoda Y, Matsuo E, Suzuki K, Hamamoto I, Yamashita T
J Virol. 2007; 81(16):8601-12.
PMID: 17553880
PMC: 1951354.
DOI: 10.1128/JVI.00608-07.
Viral determinants of resistance to treatment in patients with hepatitis C.
Wohnsland A, Hofmann W, Sarrazin C
Clin Microbiol Rev. 2007; 20(1):23-38.
PMID: 17223621
PMC: 1797633.
DOI: 10.1128/CMR.00010-06.
Elicitation of strong immune responses by a DNA vaccine expressing a secreted form of hepatitis C virus envelope protein E2 in murine and porcine animal models.
Li Y, Kang H, Babiuk L, Liu Q
World J Gastroenterol. 2006; 12(44):7126-35.
PMID: 17131474
PMC: 4087773.
DOI: 10.3748/wjg.v12.i44.7126.
Oligomerization of hepatitis C virus core protein is crucial for interaction with the cytoplasmic domain of E1 envelope protein.
Nakai K, Okamoto T, Kimura-Someya T, Ishii K, Lim C, Tani H
J Virol. 2006; 80(22):11265-73.
PMID: 16971440
PMC: 1642162.
DOI: 10.1128/JVI.01203-06.
Assembly of HCV E1 and E2 glycoproteins into coronavirus VLPs.
Jourdan N, Godeke G, Penaud M, Mottola G, Sorrentino A, Rottier P
Arch Virol. 2006; 151(10):2085-94.
PMID: 16648962
PMC: 7087226.
DOI: 10.1007/s00705-006-0769-0.
Functional analysis of hepatitis C virus envelope proteins, using a cell-cell fusion assay.
Kobayashi M, Bennett M, Bercot T, Singh I
J Virol. 2006; 80(4):1817-25.
PMID: 16439538
PMC: 1367170.
DOI: 10.1128/JVI.80.4.1817-1825.2006.
Characterization of infectious retroviral pseudotype particles bearing hepatitis C virus glycoproteins.
Flint M, Logvinoff C, Rice C, McKeating J
J Virol. 2004; 78(13):6875-82.
PMID: 15194763
PMC: 421632.
DOI: 10.1128/JVI.78.13.6875-6882.2004.
Characterization of the genome and structural proteins of hepatitis C virus resolved from infected human liver.
Nielsen S, Bassendine M, Burt A, Bevitt D, Toms G
J Gen Virol. 2004; 85(Pt 6):1497-1507.
PMID: 15166434
PMC: 1810391.
DOI: 10.1099/vir.0.79967-0.
Effects of interferon, ribavirin, and iminosugar derivatives on cells persistently infected with noncytopathic bovine viral diarrhea virus.
Durantel D, Carrouee-Durantel S, Branza-Nichita N, Dwek R, Zitzmann N
Antimicrob Agents Chemother. 2004; 48(2):497-504.
PMID: 14742201
PMC: 321564.
DOI: 10.1128/AAC.48.2.497-504.2004.
Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles.
Hsu M, Zhang J, Flint M, Logvinoff C, Cheng-Mayer C, Rice C
Proc Natl Acad Sci U S A. 2003; 100(12):7271-6.
PMID: 12761383
PMC: 165865.
DOI: 10.1073/pnas.0832180100.
